ArticleOncogene2003
Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells.
Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 65 citations in OpenAlex.
- The AKT-p21 phosphorylation signaling axis confers poor prognosis and dacarbazine resistance in melanoma.Scientific reports · 2025Article
- Transcriptionally up-regulation of CDKN1A/p21 by TFE3 fusion proteins worsened TFE3-rearranged renal cell carcinoma.Scientific reports · 2025Article
- Integrating Vascular Phenotypic and Proteomic Analysis in an Open Microfluidic Platform.ACS nano · 2024Article
- Conjugated Oligoelectrolyte with DNA Affinity for Enhanced Nuclear Imaging and Precise DNA Quantification.Biosensors · 2024Article
- Differentially Expressed Genes Induced by Erythropoietin Receptor Overexpression in Rat Mammary Adenocarcinoma RAMA 37-28 Cells.International journal of molecular sciences · 2023Article
- Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death.Molecular cancer therapeutics · 2022Article
- Platinum drugs and taxanes: can we overcome resistance?Cell death discovery · 2021Review
- Current Perspectives on Taxanes: Focus on Their Bioactivity, Delivery and Combination Therapy.Plants (Basel, Switzerland) · 2021Review
- Guanine nucleotide binding protein like-1 (GNL1) promotes cancer cell proliferation and survival through AKT/p21Molecular biology of the cell · 2020Article
- Article
- PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin βScientific reports · 2020Article
- CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells.International journal of oncology · 2020Article
- The Multifaceted p21 (Cip1/Waf1/Cancers · 2019Review
- Article
- Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals.Oncotarget · 2016Article
- Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatment.American journal of cancer research · 2016Review
- Review
- Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.Oncotarget · 2015Article
- Differences in gene expression profiles and signaling pathways in rhabdomyolysis-induced acute kidney injury.International journal of clinical and experimental pathology · 2015Article
- LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CKI p21 is a regulator of cellular responses to microtubule damage induced by drugs such as paclitaxel (PTX). It mediates the G1 4N arrest postactivation of the spindle assembly checkpoint and protects cancer cells against PTX-induced cytotoxicity. We demonstrated here that low doses of PTX that are unable to activate the spindle assembly checkpoint, upregulate p21 by a p53-dependent pathway and induce its translocation to the cytoplasm. This cytoplasmic accumulation of p21 resulted from an AKT-dependent p21 phosphorylation leading to an association of p21 with 14-3-3. Furthermore, the cytoplasmic p21 accumulation observed in PTX-treated cells was inhibited by LY 294002, a specific PI-3 kinase inhibitor or by the expression of a dominant-negative AKT mutant. However, the kinase activity of AKT was unchanged in PTX-treated cells, suggesting that low doses of PTX could regulate p21 phosphorylation via inhibition of its dephosphorylation. As a functional consequence, we found that cytoplasmic accumulation of the phosphorylated form of p21 prevents the inhibitory effect of p21, enabling these cells to escape to the p53-dependent Gl/S and G2/M checkpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.